LOS ANGELES, CA / ACCESSWIRE / March 5, 2024 / Planet MicroCap today published a new Video Interview with Jim Martin, Co-CEO and CFO, from Cocrystal Pharma, Inc. (NASDAQ:COCP), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2) noroviruses and hepatitis C viruses, according to the company's website (see here: https://www.cocrystalpharma.com/).

Click the following link to watch the Video Interview:

Cocrystal Pharma Discusses Antiviral Therapeutics' Clinical Development and 2024 Value Catalysts

You can follow Planet MicroCap on TWITTER, LINKEDIN, YOUTUBE

Please review important disclosures on our website at: https://snn.network/terms-of-use

About Cocrystal Pharma, Inc.
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2) noroviruses and hepatitis C viruses. Cocrystal employs unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs. Full company description and for further information about Cocrystal, please visit www.cocrystalpharma.com.

About Planet MicroCap

Planet MicroCap is a global multimedia financial news, publishing and events company focused on news dissemination, providing information, data and analytics for the MicroCap investing community. We have cultivated an active and engaged audience that are interested in learning about and to stay ahead of the curve in the MicroCap space. You can subscribe to Planet MicroCap's YouTube Channel here: https://www.youtube.com/snnwire

Planet MicroCap
info@snnwire.com

SOURCE: Planet MicroCap